|
Hereditary Cancer Syndromes: MSK CATCH Program (Comprehensive Assessment, Treatment, and Prevention of Cancers with Hereditary Dispositions) |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Improving Clinical Trial Accrual: Doing More with Less |
0.50 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Inequities in Clinical Outcomes in Breast Cancer: Do Biologic Differences Based on Ancestry/Racial Identity Play a Role? |
0.50 |
03/15/2025 - 12:00am to 03/15/2026 - 12:00am |
|
Innovative Strategies to Improve Patient Access |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Integrative Medicine and the Cancer Patient |
0.50 |
08/04/2022 - 12:00am to 08/04/2025 - 12:00am |
|
Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Management of CNS Metastases in Patients with Breast Cancer |
0.75 |
03/15/2025 - 12:00am to 03/15/2026 - 12:00am |
|
Management of Immune Checkpoint Inhibitor-Related Toxicities |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Management of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease |
2.25 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Management of TP53 Mutated Mantle Cell Lymphoma |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Managing Earlier Integration of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Managing Multiple Medications – Polypharmacy |
0.50 |
08/04/2022 - 12:00am to 08/04/2025 - 12:00am |
|
Managing Pain in Cancer Survivors |
0.25 |
08/04/2022 - 12:00am to 08/04/2025 - 12:00am |
|
Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia |
1.00 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Myelodysplastic Syndromes: Treatment Updates and Emerging Data |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Facebook
Twitter
LinkedIn
Forward